/PRNewswire/ Vensica Therapeutics ("Vensica"), a clinical stage biopharmaceutical company, announced that it has signed a strategic collaboration agreement.
wMerz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced today that they have entered
Merz Healthcare Breaks Even Despite COVID-19 Pandemic in Fiscal Year 2019/20
Partnership with Gwyneth Paltrow and investment in start-up Brooklyn Soap Company
Investments in the new organizational structure pay off in times of COVID-19: Focus on customer needs have proven their worth
Merz Healthcare in Frankfurt is a globally operating, diversified company with three independently operating businesses: Merz Aesthetics, Merz Therapeutics and Merz Consumer Care.
In fiscal year 2019/20, Merz Healthcare revenue amounted to EUR 981.5 million, a moderate decline of 10.3% compared to the prior-year figure.
The operating profit in the past fiscal year was EUR 38.8 million. The decline compared with the prior-year EBIT was expected due to the COVID-19 crisis. After an excellent start to the fiscal year, COVID-19 contributed to the reduction in earnings, particularly in the second half of the year.
Merz Healthcare Breaks Even Despite COVID-19 Pandemic in Fiscal Year 2019/20 FRANKFURT, Germany (Business Wire) Merz Healthcare in Frankfurt is a globally operating, diversified company with three independently operating businesses: Merz Aesthetics, Merz Therapeutics and Merz Consumer Care.
In fiscal year 2019/20, Merz Healthcare revenue amounted to EUR 981.5 million, a moderate decline of 10.3% compared to the prior-year figure.
The operating profit in the past fiscal year was EUR 38.8 million. The decline compared with the prior-year EBIT was expected due to the COVID-19 crisis. After an excellent start to the fiscal year, COVID-19 contributed to the reduction in earnings, particularly in the second half of the year.